Inactivation of γ-secretases leads to accumulation of substrates and non-Alzheimer neurodegeneration by Acx, Hermien et al.
Research Article
Inactivation of c-secretases leads to accumulation
of substrates and non-Alzheimer neurodegeneration
Hermien Acx1,2,†, Lutgarde Serneels1,2,†, Enrico Radaelli1,2, Serge Muyldermans3, Cécile Vincke3,
Elise Pepermans1,2, Ulrike Müller4, Lucía Chávez-Gutiérrez1,2,* & Bart De Strooper1,2,5,**
Abstract
c-Secretases are a family of intramembrane cleaving aspartyl
proteases and important drug targets in Alzheimer’s disease. Here,
we generated mice deficient for all c-secretases in the pyramidal
neurons of the postnatal forebrain by deleting the three anterior
pharynx defective 1 (Aph1) subunits (Aph1abc cKO Cre+). The mice
show progressive cortical atrophy, neuronal loss, and gliosis. Inter-
estingly, this is associated with more than 10-fold accumulation of
membrane-bound fragments of App, Aplp1, Nrg1, and Dcc, while
other known substrates of c-secretase such as Aplp2, Lrp1, and
Sdc3 accumulate to lesser extents. Despite numerous reports link-
ing neurodegeneration to accumulation of membrane-bound App
fragments, deletion of App expression in the combined Aph1 knock-
out does not rescue this phenotype. Importantly, knockout of only
Aph1a- or Aph1bc-secretases causes limited and differential
accumulation of substrates. This was not associated with neuro-
degeneration. Further development of selective Aph1-c-secretase
inhibitors should be considered for treatment of Alzheimer’s
disease.
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Introduction
c-Secretases are a family of ubiquitously expressed membrane
proteases consisting of four proteins: presenilin (PSEN), anterior
pharynx defective-1 (APH1), nicastrin (NCT), and presenilin
enhancer-2 (PEN-2) (De Strooper, 2003; Edbauer et al, 2003;
Takasugi et al, 2003). Missense mutations in PSEN are the most
important cause of familial Alzheimer’s disease (FAD) (Sherrington
et al, 1995) (for an overview, see http://www.alzforum.org/mu
tations). These mutations affect the proteolytic processing of APP
toward Ab peptides. In contrast to general assumptions that their
effects are quantitative, that is, increase Ab42 generation, the changes
are mainly qualitative, shifting the spectrum of Ab peptides toward
longer versions that are apparently able to seed disease (Borchelt et al,
1996; Duff et al, 1996; Scheuner et al, 1996; Bentahir et al, 2006;
Cha´vez-Gutie´rrez et al, 2012; Szaruga et al, 2015; Veugelen et al,
2016).
In human, two different PSEN1 or PSEN2 and APH1A or APH1B
variants can combine to generate four different enzyme complexes,
whereas in rodents the Aph1b gene is duplicated, giving an addi-
tional Aph1c variant and resulting in 6 different rodent complexes
(De Strooper, 2003; He´bert et al, 2004; Shirotani et al, 2004;
Serneels et al, 2005). Alternative splicing of PSEN and APH1 genes
further adds to the complexity of the c-secretase family (Gu et al,
2003; He´bert et al, 2004; Shirotani et al, 2004). The Aph1b and
Aph1c genes in rodent are almost identical and located next to each
other in the rodent genome; thus, we consider in our mouse experi-
ments the Aph1b and Aph1c genes together as a homologue of the
single human APH1B gene. The c-secretase proteases cleave a broad
spectrum of substrates, but it remains unclear whether specific
substrates are cleaved by specific complexes (Kopan & Ilagan, 2004;
Beel & Sanders, 2008; Jurisch-Yaksi et al, 2013; Sannerud et al,
2016). Cellular context is likely critical to understand the physiologi-
cal functions of the different c-secretases and their potential
substrate selectivity (Sannerud et al, 2016). The recent failures of
broad spectrum c-secretase inhibitors in the clinic (Doody et al,
2013; Coric et al, 2015) dramatically illustrates our lack of basic
knowledge of the c-secretases (De Strooper, 2014).
Inactivation of either Nct or both the Psen1&2 subunits in the
excitatory neurons of the postnatal forebrain causes age-dependent
neuronal loss, accompanied by astrocytosis and microgliosis with-
out Ab amyloidosis (Beglopoulos et al, 2004; Saura et al, 2004;
Tabuchi et al, 2009; Wines-Samuelson et al, 2010). These
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phenotypes are not observed when only Psen1 is inactivated, but
additional inactivation of one or two Psen2 alleles causes neurode-
generation (Watanabe et al, 2014), indicating that a critical dose of
c-secretase activities is needed to maintain homeostasis of pyrami-
dal neurons. The question has been raised whether the neurodegen-
eration in these knockout mice is relevant to processes occurring in
Alzheimer’s disease (Saura et al, 2004; Xia et al, 2016) or whether
this reflects a non-typical neurodegeneration triggered by severe
functional defects caused by the full knockout of all c-secretases
(Veugelen et al, 2016).
The loss of function of c-secretases leads theoretically to the
accumulation of their many substrates in the cell membrane. This
has mostly been investigated in cell culture, and it is unclear to
what extent this happens also in vivo, in the brain. It is also
unclear whether the selective inactivation of one or more types of
c-secretases leads to differential effects on distinct substrates. If
one hypothesizes that c-secretase deficiency causes Alzheimer
relevant neurodegeneration (Saura et al, 2004), this could theoret-
ically be mediated by accumulation of unprocessed APP-carboxy-
terminal fragments (CTFs) (Pera et al, 2013). Artificial
overexpression of APP-CTFs is known to be neurotoxic in vitro
(Yankner et al, 1989; Fukuchi et al, 1993), and in vivo (Neve
et al, 1996; Oster-Granite et al, 1996). Inhibition of c-secretase
activity, but not b-secretase activity, causes synaptic and memory
deficits in a mouse model of AD which is associated with accu-
mulation of APP-CTF (Tamayev et al, 2012), suggesting that APP-
CTFs, next to Ab peptides, are also toxic species causing neurode-
generation. In the same line, chronic administration of a c-secre-
tase inhibitor, lowering Ab but increasing APP-CTF, worsened
cognitive function in mice overexpressing APP, while a “second
generation” c-secretase modulator that only affected Ab produc-
tion without changing APP-CTF levels, did not (Mitani et al,
2012). It should be noticed that the models used in these studies
have strong overexpression of APP, and it remains to be seen
whether such toxic APP-CTF level can be induced under physio-
logical expression of App. It remains also unclear whether the
accumulation of APP-CTFs is a general phenomenon in Alzheimer’s
disease (Pera et al, 2013) and how APP-CTFs would trigger or
add to neurodegeneration, although various signaling pathways,
some affecting neurite growth and dendritic arborization, have
been proposed (Deyts et al, 2012).
Here we addressed some of these questions by genetically
inactivating Aph1a- or Aph1bc-c-secretases selectively in pyrami-
dal neurons and by generating the triple Aph1abc knockout in
these cells (Aph1abc cKO Cre+). We confirm that full knockout of
all c-secretases, as seen with the Aph1abc cKO Cre+, causes
progressive neurodegeneration. Interestingly, this is not seen with
the single Aph1a or Aph1bc cKO Cre+. The neurodegeneration in
the Aph1abc cKO Cre+ mice was correlated with strong accumula-
tion of several substrates, including a 20-fold increase in App-CTF
levels, while the single cKOs showed only mild but differential
accumulation of various substrates, demonstrating for the first
time the in vivo selectivity of the two different c-secretase
subtypes. Finally, we find that deletion of the App gene does not
modulate the neurodegenerative phenotype in the Aph1abc cKO
Cre+ animals, indicating that App-CTFs are not necessarily
involved in the mechanism(s) causing neurodegeneration in these
animals.
Results
Loss of c-secretase activity in CaMKIIa-positive neurons
causes neurodegeneration
Here we fully inactivated c-secretases by targeting the three Aph1
genes in mouse pyramidal forebrain neurons. Mice homozygous for
the floxed Aph1 genes show already a depletion of the expression of
the Aph1 subunits (Fig EV1) probably because of the insertion of
the loxP sites. More importantly, the expression of other c-secretase
components is not affected (Fig EV1, quantified in Fig EV2A), and
c-secretase activity as evaluated by APP-CTF substrate accumulation
or Ab generation is not decreased in the Aph1abc cKO Cre condi-
tion (Fig EV2B and C). The mice do not show any phenotype when
cortical thickness, neuronal cell counts per unit of sagittal length or
inflammatory responses are evaluated at 9 months (Fig 1A and B).
Furthermore, no major phenotypes have manifested over the
10 years that the colony has been maintained in our animal facility.
For the next experiments, we consider therefore the mice with the
floxed alleles as control, despite the lower expression of Aph1 sub-
units. We crossed them with mice that express Cre recombinase via
the CaMKIIa promoter in order to delete the three Aph1 genes in
pyramidal neurons only (Aph1abc cKO Cre+). Western blots of
cortical lysates show 30% less expression of Aph1a, while Aph1b
expression was already undetectable in the Cre mice (Fig EV1).
However, the effect of Cre-dependent deletion of the Aph1 compo-
nents in the pyramidal neurons resulted in decreased Nct, Pen-2 and
Psen1 expression levels by  50% (Fig EV2A). App-CTF levels were
increased by 20-fold and Ab40 and Ab42 levels were both decreased
by  35%, showing that c-secretase activity in these neurons is
strongly affected (Fig EV2B and C). The residual expression of
c-secretase components detected in the cortical lysates is explained
by the neurons, glia and other cells that do not express Cre from the
CaMKIIa promotor.
Immunohistochemical analyses of the brains of 3-month-old
Aph1abc cKO Cre and Aph1abc cKO Cre+ mice (Fig EV4) show no
difference in cortical thickness (P > 0.99), whereas at 6 months of
age, serious cortical atrophy is seen (decrease of 10%; P = 0.0009)
and the phenotype was further increased in 9-month-old Aph1abc
cKO Cre+ mice (decrease of 22%; P < 0.0001) demonstrating that
the genetic inactivation of all different c-secretase complexes in
pyramidal forebrain neurons leads to progressive cortical atrophy
(Fig EV4). The loss of neurons in the Aph1abc cKO Cre+ mice was
further confirmed by quantification of NeuN staining at 9 months
(799  41 NeuN+ cells/mm cortical length versus 1,141  16
NeuN+ cells/mm cortical length, Aph1abc cKO Cre+ versus Cre)
(Fig 1A and B). This was accompanied by increased Iba1
(1.44  0.23% versus 0.75  0.01% Iba1-positive area) (Fig 1B)
and Gfap (13.56  0.75% versus 2.04  0.90% Gfap-positive area)
(Fig 1B) immunoreactivity, diagnostic of microgliosis and astroglio-
sis, respectively.
Single Aph1 knockouts do not result in neurodegeneration
We have previously shown that depletion of Aph1b in mouse brain
is sufficient to lower significantly Ab generation in APP/PS1 mice
(Serneels et al, 2009). Thus, we investigated the effects of the selec-
tive inactivation of the distinct Aph1-type enzyme complexes by
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Figure 1. Loss of complete c-secretase activity in CaMKIIa-expressing neurons leads to neurodegeneration.
A Hematoxylin/eosin staining of sagittal brain slices of 9-month-old mice. Upper panel scale bar = 1,100 lm; lower panel scale bar = 195 lm. Cortical atrophy is
present in Aph1abc cKO Cre+ mice, whereas absent in Aph1abc cKO Cre mice.
B NeuN, Iba1 and Gfap immunofluorescent labeling of parietal cortex of 9-month-old mice. Scale bar = 115 lm. Full cortical thickness counts of NeuN-positive cells, as
determined via NeuN staining, was decreased in Aph1abc cKO Cre+ mice. Reactive gliosis, as determined via Gfap and Iba1 staining, is present in Aph1abc cKO Cre+
mice, whereas absent in Aph1abc cKO Cre mice.
Data information: Mean, standard deviation, and P-values are shown. One-way ANOVA and Dunnett’s post hoc test. CTX = cortex; cc = corpus callosum; ns = not
statistically significant. N = 3.
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generating mice with single Aph1a or single Aph1bc KO in the
CaMKIIa-positive neurons. Remarkably, App-CTF is only accumulat-
ing in the brain of Aph1bc cKO Cre+ animals pointing toward an
important role of Aph1bc-complexes in the processing of App-CTFs
in these neurons (Fig EV3B and C). In line with this observation, Ab
levels are only decreased in the Aph1bc cKO Cre+ condition (Ab40
shows a trend for decrease, Ab42 is significantly decreased in the
Aph1bc cKO Cre+ condition).
The current data suggest that Aph1bc is functionally more promi-
nent than Aph1a at least in pyramidal neurons and with regard to
the processing of App-CTFs. Interestingly and in contrast to the
triple Aph1abc cKO Cre+ mice, the single Aph1a cKO Cre+ or
Aph1bc cKO Cre+ mice do not show any signs of neurodegeneration,
as demonstrated by the absence of atrophy of the cortex (Fig 2A),
neuronal loss or inflammatory responses at 6 months of age
(Fig 2B).
Neurodegeneration in triple Aph1 knockout mice is associated
with massive accumulation of substrates
We analyzed to what extent C-terminal fragments of known c-secre-
tase substrates were accumulating in the different Aph1 cKO brains
using Western blot. In the triple Aph1abc cKO Cre+ mice, we see
strong accumulation of C-terminal fragments of App (18-fold), Aplp1
(16-fold), Nrg1 (13-fold), and Dcc (11-fold) and a milder accumula-
tion of Aplp2 (1.5-fold), Lrp1 (2.4-fold), and Sdc3 (2.6-fold) (Fig 3A
and C). Expression of the full-length proteins is not altered (Fig 3A).
Remarkably, in the single Aph1 cKO Cre+ animals (Fig 3B and D) we
see no or much more limited effects on, and differential alterations
of the different substrates. For example, the C-terminal fragments of
App, Aplp1, and Aplp2 are mildly accumulating in Aph1bc cKO Cre+
brains (1.7-, 2- and 1.7-fold, respectively), whereas they are
unchanged in Aph1a cKO Cre+ brains. On the other hand, Sdc3 accu-
mulates to a similar level in both Aph1a and Aph1bc cKO Cre+
brains, while Nrg1 and Lrp1 are accumulating in both, but slightly
more in Aph1a than Aph1bc cKO Cre+ brains (3.5-fold versus 2.5-
fold for Nrg1 and 1.6-fold versus 1.3-fold for Lrp1). These data
demonstrate for the first time in vivo substrate selectivity of the
two different c-secretase subtypes. One should take into account
that the changes only reflect what happens in pyramidal neurons.
App is not involved in the neurodegeneration of the triple
KO mice
We notice that one of the strongest accumulating substrates in the
Aph1abc cKO Cre+ mice is App C-terminal fragment (18-fold)
(Fig 3A and C). To examine the cellular pattern of App-CTF accu-
mulation, we performed immune staining with an antibody that
recognizes the C-terminus of App (Fig 4). Specificity of the staining
is clear from the staining of App KO sections (Fig 4). The immuno-
histochemistry confirms entirely the strong signals we saw for App
C-terminus in Western blot. Notably, while in the control brains the
staining was mainly restricted to the cell bodies, in Aph1abc cKO
Cre+ brains the staining for App increased in the neurites in CA3
and dentate gyrus regions of the hippocampus and in the parietal
cortex overlying the hippocampus (Fig 4). As App-FL levels are
unchanged in the Aph1abc cKO Cre+ lysates (Fig 3A), and App
intracellular domain fragments (App-ICDs) cannot be generated
without active c-secretase complexes, the increased staining must
originate from the accumulation of App C-terminal fragments, as
independently confirmed by Western blot analysis (Fig 3A).
We finally tested the hypothesis whether App-CTF accumulation
could cause the neurodegeneration in the Aph1abc cKO Cre+ mice
(Fig 5) by crossing them with the APP null mice. The loss of App,
by itself, does not cause cortical neurodegeneration (Fig 5). Interest-
ingly, loss of App did not modify the progressive cortical atrophy in
the Aph1abc cKO Cre+, as evaluated by measuring the thickness of
the neocortex (Fig 5A), neuronal count and reactive micro- and
astrogliosis in 9-month-old mice (Fig 5B). Of notice, App KO mice
displayed equal levels of NeuN, Iba1 and Gfap immunoreactivity
compared to wild-type control mice, showing that depletion of App,
on its own, has also no effect on neuronal survival and gliosis
(Fig 5B). Altogether, these results demonstrate that the accumula-
tion of App-CTFs is not the cause of the neurodegeneration observed
in Aph1abc cKO Cre+ mice.
Discussion
Here we demonstrate that the combined inactivation of the three
Aph1 subunits in postnatal pyramidal neurons in the mouse brain
leads to a similar neurodegenerative phenotype as previously seen
with Nct and Psen1&2 knockouts in these cells (Saura et al, 2004;
Tabuchi et al, 2009; Wines-Samuelson et al, 2010). Importantly, we
do not observe this progressive neurodegeneration in single Aph1a
or Aph1bc cKO Cre+ mice. The data thus support the possibility that
different c-secretases can at least partially compensate for each
other’s loss.
Introducing LoxP sites into the genes encoding the different
Aph1 proteins caused on its own a strong decrease in their protein
expression (Fig EV1). This partial loss of function mutation (hypo-
morphic mutation) had little effect on the stability of the other
c-secretase subunits (Figs EV1 and EV2A), and on c-secretase enzy-
matic activities as deduced from App-CTF and Ab levels (Fig EV2B
and C). This claim is further corroborated by the lack of neurode-
generation, neuronal loss, astrogliosis or microgliosis in these mice
(Fig 1). With the expression of Cre driven by the CaMKIIa promotor
we expect that the loxP sites will recombine, resulting in complete
abrogation of Aph1 expression in pyramidal neurons of the fore-
brain. Other neurons and glia cells continue expressing c-secretases
normally, and therefore, Western blots of cortical extracts are
providing only a crude estimate of the effects (Figs EV1 and EV2A).
However, App-CTF and other substrates accumulate and decreased
Ab generation is readily observed (Fig EV2B and C). The progres-
sive neuronal loss and progressive astro- and microgliosis suggest
that c-secretase activity is essential in these neurons for their
survival (Fig 1). The mechanism(s) underlying the neurodegenera-
tive process remain unclear, but the age dependency and the
progressive nature of the disorder in the mice (Fig EV4) have led to
speculations that full c-secretase knockout reflects what occurs in
FAD patients (Saura et al, 2004; Xia et al, 2016). Our data suggest
however underlying mechanisms that are quite different from the
processes causing AD. First, the full and indiscriminate inactivation
of c-secretases in pyramidal neurons leads to huge accumulations of
various substrates like App, Aplp1, Nrg1 and Dcc, while Aplp2,
Lrp1 and Sdc3 accumulate to lesser extents (Fig 3). To our
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knowledge, such strong accumulations of membrane-bound protein
fragments have never been observed in AD patients. Second, the
phenotype in the triple KO mouse was not affected by the cross with
App KO mouse, which deletes the strongly accumulating App-CTF
(Fig 5). The hypothesis that the neurodegeneration in the full
c-secretase knockout animals is AD related (Saura et al, 2004;
Tabuchi et al, 2009; Xia et al, 2016) is difficult to maintain if APP
does not modify this phenotype. Finally, as we show here,
A
B
Figure 2. No neurodegenerative phenotype observed in single Aph1a and Aph1bc cKO Cre+ mice.
A Hematoxylin/eosin staining of sagittal brain slices of 6-month-old mice. Scale bar = 195 lm. Cortical atrophy is absent in Aph1a cKO Cre+ and Aph1bc cKO Cre+ brains.
B NeuN, Iba1, and Gfap immunofluorescent labeling of parietal cortex. Scale bar = 115 lm. Full cortical thickness counts of NeuN-positive cells, as determined via
NeuN staining, was comparable in control, Aph1a cKO Cre+, and Aph1bc cKO Cre+ mice. Reactive gliosis, as determined via Gfap and Iba1 staining, is absent in Aph1a
cKO Cre+ and Aph1bc cKO Cre+ mice.
Data information: Mean and standard deviation are shown. One-way ANOVA and Dunnett’s post hoc test. ns = not statistically significant. N = 3.
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C D
Figure 3. Differential accumulation of substrates in vivo.
Hippocampal lysates were analyzed by immunoblotting using antibodies against the C-terminus of the different c-secretase substrates. For every substrate, full-length (FL) or the
80-kDa furin-cleavedLRP fragmentandC-terminal fragments (CTF)are shown.b-Actinwasusedas loadingcontrol tonormalize thedata.Molecularweightmarkersaredepicted inkDa.
A Western blot analysis of hippocampal lysates from Aph1abc cKO Cre and Aph1abc cKO Cre+ mice, three representative samples are shown. Five mice per genotype
were analyzed.
B Western blot analysis of hippocampal lysates from wild-type, Aph1a cKO Cre+, and Aph1bc cKO Cre+, three representative samples are shown. Ten mice per genotype
were analyzed.
C FL and CTF protein levels in panel (A) were quantified and FL/CTF ratios are plotted, normalized to Aph1abc cKO Cre controls. Significant differences in protein
expression between controls and Aph1abc cKO Cre+ mice were assessed using Student’s t-test per protein (GraphPad), followed by false discovery rate (FDR) P-value
adjustments (R, version 3.3.1) to correct for multiple protein testing. Mean, SEM, and P-values are shown, ns = not statistically significant, N = 5.
D FL and CTF protein levels in panel (B) were quantified and FL/CTF ratios are plotted, normalized to wild-type controls. Differences in protein expression between wild-
type, Aph1a cKO Cre+, and Aph1bc cKO Cre+ were computed using one-way ANOVA per protein, followed by FDR P-value adjustment of the Tukey’s post hoc test. Mean,
SEM, and P-values are shown, ns = not statistically significant, N = 10.
Source data are available online for this figure.
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neurodegeneration is only observed when all 6 c-secretases are inac-
tivated together in the mouse neurons (Figs 1 and 2). Such situation
(with four human c-secretases all inactivated) is highly unlikely to
occur in heterozygous FAD patients carrying partial loss of function
mutations (Szaruga et al, 2015; Veugelen et al, 2016).
As the accumulation of App-CTFs by itself is not causal to the
neurodegeneration in the triple KO mice, two other hypotheses
remain to be further investigated. First, it could be that the neurode-
generation is a consequence of the huge accumulation of various
c-secretase substrates in the cell membrane of the neurons. Over-
crowding of the membrane with transmembrane domains of various
proteins is not unlikely to cause havoc in neurons in a non-specific
way. The alternative possibility remains that the neurodegeneration
is caused by deficient processing of a specific substrate crucially
important for intracellular signaling and maintenance of neuronal
homeostasis. App (as shown here) and Notch1&2 (Zheng et al,
2012) are already excluded. It is clear that further identification and
validation of endogenous substrates of the different c-secretases in
the adult brain is of great importance to understand better the
biological role of these intriguing proteases (De Strooper, 2014). For
instance, and highly relevant to AD therapy, the way the
non-selective c-secretase inhibitors semagacestat (Doody et al,
2013) and avagacestat (Coric et al, 2015) were dosed in the failed
clinical trials has likely caused short but complete blocks of all
enzymes at the same time (discussed in De Strooper, 2014). This
repetitive complete blockage of all c-secretases mimics in a pharma-
cological way the situation in the Aph1abc cKO Cre+ mice. Although
we did not perform pharmacological experiments to investigate this
further, we speculate that intermittent accumulations of transmem-
brane domain fragments in neurons might have contributed to the
aggravated cognitive performance of the treated patients.
The most important and hope giving result of the current work is
the very mild effects of single Aph1a or Aph1bc knockouts in the
brain of adult mice (Figs 2 and 3). Analysis of the accumulation of
different substrates shows that quantitative effects on substrate
levels remain relatively small with maximum a doubling of the
normal levels of specific substrates (to be compared with the 10- to
18-fold changes seen with some substrates in the full Aph1abc cKO
Cre+ animals). Remarkably, the Aph1bc cKO Cre+, even when
limited to the forebrain pyramidal neurons, has a significant effect
on Ab42 generation (Fig EV3C) confirming previous findings with
the Aph1bc full knockout which could prevent amyloidosis and
cognitive decline in an APP overexpressing AD model (Serneels
et al, 2009). Of note, a certain substrate specificity of the
Figure 4. App-CTFs accumulate in the neurites and synaptic compartments in Aph1abc cKO Cre+ brains.
Immunostainingwith an antibody recognizing the C-terminal part of App. Sagittal brain slices from App KOmice were used to show the specificity of the antibody. Conditional
deletion of the Aph1 genes in the pyramidal neurons causes accumulation of App-CTFs in the neurites in the hippocampal and cortical areas. Zoom-ins on the dentate gyrus
(DG) and CA3 region of the hippocampus and the parietal cortex overlying the hippocampus show that expression of App and App-CTFs is mainly confined to the neuronal
somata in control brains, whereas App-CTFs accumulate in the neurites and synaptic compartments in Aph1abc cKO Cre+ brains. Scale bar for left panels = 390 lm; scale bar
for central panels = 150 lm; scale bar for right panels = 110 lm.
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c-secretases in function of their Aph1 subunits is observed: App,
Aplp1 and Aplp2 are mildly accumulating in Aph1bc cKO Cre+
brains, but not in Aph1a cKO Cre+ brains, while Nrg1 and Lrp1 are
accumulating slightly more in Aph1a than Aph1bc cKO Cre+ brains
(Fig 3). Differential expression and co-localization of substrates and
enzyme complexes at the cellular or even subcellular level
A
B
Figure 5. App depletion does not rescue cortical atrophy and gliosis in Aph1abc cKO Cre+ mice.
A Hematoxylin/eosin staining of sagittal brain slices of 9-month-old mice. Scale bar = 195 lm. Progressive cortical atrophy is present to the same extent in Aph1abc cKO
Cre+ and Aph1abc cKO Cre+ × App KO mice, whereas absent in control and App KO mice.
B NeuN, Iba1, and Gfap immunofluorescent labelings of parietal cortex. Scale bar = 115 lm. Full cortical thickness counts of NeuN-positive cells, as determined via
NeuN staining, was comparable in control and App KO mice, whereas decreased to the same extent in Aph1abc cKO Cre+ and Aph1abc cKO Cre+ × App KO mice.
Reactive gliosis, as determined via Gfap and Iba1 staining, is present to the same extent in Aph1abc cKO Cre+ and Aph1abc cKO Cre+ × App KO mice, whereas absent in
control and App KO mice.
Data information: Mean, standard deviation, and P-values are shown, ns = not statistically significant. One-way ANOVA and Dunnett’s post hoc test. N = 3.
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(Sannerud et al, 2016) are contributing to this, but also distinctive
intrinsic enzymatic properties of the different complexes (Mas-
trangelo et al, 2005), in which the Aph1 proteins act as allosteric
subunits, may account for differential processing of substrates (Acx
et al, 2014).
Altogether, we show that the loss of the three Aph1 subunits in
pyramidal neurons of the postnatal forebrain leads to a progressive
neurodegenerative phenotype accompanied by the severe accumula-
tion of c-secretase substrates. Depletion of App did not modulate
cortical atrophy, neuronal loss or inflammation, which suggests that
the resulting phenotype is not typical for AD. Since c-secretase
substrate accumulation is limited in single Aph1a or Aph1bc cKO
Cre+ mice, and not associated with a neurodegenerative phenotype,
further development of selective c-secretase inhibitors, and in
particular drugs targeting the combination PSEN1/APH1B, might be
considered for treatment of Alzheimer’s disease. A word of caution
is indicated, however. First, we analyzed mice only at biochemical
and microscopic-morphological levels, and we can thus not make
any statements with regard to potential behavioral or electrophysio-
logical abnormalities in the different mice investigated here. Second,
it should be stressed that we here only inactivate c-secretases in
neurons that express Cre driven by the CaMKIIa promotor. Pharma-
cological inhibitors would block also c-secretases in other cells and
peripheral tissues, and therefore, further scrutiny is needed. We
previously generated full Aph1bc knockouts and have shown that
these mice are healthy and show very little problems apart from a




Mice conditionally targeted for Aph1a, Aph1bc or Aph1abc were
previously generated (Serneels et al, 2005). cKO mice were gener-
ated by crossing with Tg (CaMKIIa-Cre)T291STl mice (Jackson labora-
tory) resulting in knockout of the targeted genes in the postnatal
pyramidal neurons of the forebrain (Mayford et al, 1996; Yu et al,
2001). The Aph1a, Aph1bc and Aph1abc cKO animals were
heterozygous for the CaMKIIa-Cre transgene while Cre-negative
littermates were used as controls. Apptm2Cwe (in this study called
App KO) animals were previously generated (Li et al, 1996). Simple
crossings led to the Aph1abc cKO × App KO animals. All colonies
were kept on an inbred C57Bl/6J background. Both females and
males were included in the study. The morphological and biochemi-
cal analyses were done on different time points (3, 6, or 9 months
of age); this is mentioned in the respective figure legends. Mice are
housed in cages enriched with wood-wool and shavings as bedding,
given access to water and food ad libitum. All experiments were
approved by the Ethical Committee on Animal Experimenting of the
University of Leuven (KU Leuven).
Antibodies
Rabbit polyclonal antibodies against Psen1-NTF (B19), Aph1a
(B80.3), Nct (9C3), Pen-2 (B126), and App C-terminus (B63.3) have
been described (Annaert et al, 2001; Esselens et al, 2004). Aph1bc
(L82) was generated in the laboratory by immunizing rabbits with a
QDKNFLLYNQRSR peptide. Aplp1 (W1CT) and Aplpl2 (W2CT) were
a gift from D. Walsh, and Syndecan3 (2E9) was a gift from G. David.
Commercially available antibodies were as follows: anti-Psen2-CTF
(D30G3) from Cell Signaling, anti-beta-actin (A5441) from Sigma,
Lrp1 (EPR3724) from Epitomics, Dcc (A20) and Nrg1 (F-20) from
Santa Cruz, and N-cadherin (32/N-cadherin) from BD. For immuno-
histochemistry, the same App-CTFs were used (1:7,500), and further,
NeuN (1:1,000, Chemicon Millipore clone A60 #MAB377, mouse
monoclonal), Iba1 (1:900, Wako #019-19741, rabbit polyclonal), and
Gfap (1:1,000, Dako #Z0334, rabbit polyclonal). ELISA-capturing
antibodies were as follows: JRF/cAb40/28 for Ab40 and JRF/cAb42/
26 for Ab42 from Janssen Pharmaceutica (Beerse, Belgium). Detection
antibody huAB25-HRPO was obtained from Janssen Pharmaceutica.
Tissue preparation for morphological evaluation
The mice were sacrificed with a mixture of xylazine (25 mg/ml),
ketamine (20 mg/ml) and atropine (20 ng/ml), followed by intrac-
ardial perfusion of ice-cold PBS and 4% paraformaldehyde solution.
The head was further post-fixed in 4% paraformaldehyde for 48 h
at 4°C. The brain was removed, cut in half along the midsagittal
plane and processed for paraffin embedding (Thermo Scientific
ExcelsiorTM AS Tissue Processor and HistoStarTM Embedding Work-
station). Serial sagittal sections of 6 lm were obtained (Thermo
Scientific Microm HM355S microtome). Sections were mounted on
SuperfrostTM Plus Adhesion slides (Thermo Scientific) and stained
with hematoxylin and eosin (H&E, Diapath #C0302 and #C0362) or
with antibodies. Sections for App-CTF immunohistochemistry were
deparaffinized in xylene and then rehydrated in ethanol series (100,
95 and 70%) and distilled H2O. Endogenous peroxidase was inacti-
vated with 3% H2O2 (15 min, RT). Epitope retrieval was done in
citrate buffer (pH 6) using 2100 Retriever. Sections were blocked in
1% BSA solution for 40 min at RT and then incubated overnight at
4°C with the primary antibody followed by 1-h incubation with the
secondary antibody. EnVision+/HRP reagent (Dako K400311) was
applied on sections for 45 min at RT. Immunoreactivity was
revealed with the diaminobenzidine chromogen reaction (Peroxi-
dase substrate kit, DAB, SK-4100; Vector Lab). Slides were counter-
stained in hematoxylin, dehydrated in ethanol series, cleared in
xylene, and permanently mounted with a resinous mounting
medium (Micromount Diapath, #60200). 0.1% Tween-20–TBS was
used as washing buffer. Immunofluorescence staining for NeuN,
Iba1, and Gfap was performed on an automated Ventana Discovery
Ultra platform using Alexa Fluor 568 donkey anti-mouse (1:200,
Molecular Probes A10037) or Alexa Fluor 488 donkey anti-rabbit
(1:200, Molecular Probes A-21206) secondary antibodies and DAPI
(Sigma-Aldrich D9542) as nuclear counterstain. Imaging and analy-
sis of the bright field and immunofluorescence samples were
performed with a Leica DM2500 microscope and a motorized stage-
equipped Leica DMRB fluorescence microscope, respectively.
Analysis of cortical thickness, neuronal density and gliosis
The thickness of parieto-occipital cortex overlying the CA1
hippocampal field was measured in four sagittal H&E-stained
brain sections spaced 30 lm apart. The degree of gliosis was deter-
mined by means of Gfap and Iba1 immunofluorescence. Gfap- or
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Iba1-positive areas were measured in two sagittal brain sections
spaced 30 lm apart for a total neocortical area of ~3 mm2. The
degree of neuronal loss in the neocortex was determined by means
of NeuN immunofluorescence. For each animal two sagittal brain
sections spaced 30 lm apart were used. Full cortical thickness
counts of NeuN-positive cells were assessed in comparable regions
of the parieto-occipital cortex. Full cortical thickness counts were
then normalized to the total sagittal length of the cortical fields
considered in the evaluation (i.e. ~2 mm for each animal). Compara-
tive morphometric analyses were performed on highly homologous
and anatomically matched sagittal sections selected based on the
recognition of specific neuroanatomic landmarks (Garman et al,
2016). The Mouse Allen Brain Atlas (http://atlas.brain-map.org/)
was used as neuroanatomic reference. Image analysis was performed
using ImageJ software. For each genotype and each time point, three
animals were analyzed. Genders were mixed. The morphological
evaluation was carried out blindly.
Tissue preparation for cortical and hippocampal lysates
Cortices and hippocampi were dissected and homogenized in a
Dounce homogenizer in 10 ml/mg tissue of STE buffer (320 mM
sucrose, 5 mM Tris–HCl (pH 7.2), 1 mM EGTA) + complete protease
inhibitors (Roche). The homogenate was centrifuged at 800 g for
10 min at 4°C. 750 ll of the supernatant was further ultracen-
trifuged at 100,000 g for 60 min at 4°C. The pellet (containing
synaptosomes as well as membranous organelles such as Golgi,
endoplasmic reticulum and plasma membrane) was resuspended in
STE buffer + 1% TX-100 and incubated on ice for 30 min. The
supernatant was collected after centrifugation at 19,000 g for
30 min at 4°C. Equal amounts of protein were taken and analyzed
by SDS–PAGE and semi-quantitative Western immunoblot.
Tissue preparation for Ab ELISA
Brains were homogenized in 7.5 volumes of 0.4% diethylamine/
50 mM NaCl/1× PI-EDTA solution using FastPrep Lysing Matrix D
Tubes in a FastPrep Instrument for 45 s at 6 m/s. Samples were
centrifuged for 5 min at 19,000 g at 4°C. Supernatant was trans-
ferred to prechilled tubes and ultracentrifuged at 250,000 g for
30 min at 4°C. Supernatant was neutralized by adding 1/10 volume
0.5 M Tris–HCl (pH 6.8).
Expanded View for this article is available online.
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